Firstly, this study was aimed to explore the the synergistic effect of the  the three Tibetan prescriptions, "Shanhu", "Ruyi Zhenbao", and "Chenxiang" pills, on a permanent occlusion of middle cerebral artery model (pMCAO), and which were respectively oral administration at morning, noon and night. Secondly, the active compound in these three Tibetan prescriptions were recognized. Finally, the pharmacodynamic effect of the active compound were conducted a comprehensive research.

Comparing to the individual groups, the combination group could significant reduce volume of the cerebral infarction, and at the same time reduce the neuronal damage and apoptosis in the penumbra. These results indicated that the three Tibetan prescriptions have a synergistic therapeutic effect in the treatment of cerebral ischemia injury, and exert different therapeutic effects at different times.  Monomer R could not only be recognized in the blood components, but also in the in vitro components of these three Tibetan prescriptions. It indicated that R was one of the most important the active compound in the prescriptions. Monomer R can reduce the oxidative damage and neurotoxicity of cells in vitro and promote prevent the nerve cells from injury. It can effectively reduce the cerebral ischemic injury in rats and inhibit the expression of inflammatory factors and oxidative stress in vivo. At the same time, it promotes repair of the blood-brain barrier that damages brain tissue. That Monomer R might be a candidate for ameliorating the cerebral ischemia injury.